The SPTLC1 gene (Serine Palmitoyltransferase Long Chain Base Subunit 1) encodes the SPTLC1 protein, the catalytic subunit of serine palmitoyltransferase (SPT), the rate-limiting enzyme in de novo sphingolipid biosynthesis. SPT catalyzes the condensation of L-serine with palmitoyl-CoA to form 3-ketosphinganine, the first and committed step in sphingolipid synthesis. SPTLC1 is essential for cellular membrane integrity, lipid raft formation, and signaling transduction. Mutations in SPTLC1 cause hereditary sensory and autonomic neuropathy type 1 (HSAN1), a devastating peripheral neuropathy characterized by sensory loss, ulcerations, and sometimes motor involvement. Additionally, SPTLC1 dysfunction has been implicated in Alzheimer's disease, Parkinson's disease, and metabolic disorders.
Sphingolipids are essential structural components of eukaryotic cell membranes and serve as critical signaling molecules involved in cell growth, differentiation, apoptosis, and stress responses[1]. Serine palmitoyltransferase (SPT) catalyzes the first committed step in sphingolipid biosynthesis, making it a key regulatory point for cellular sphingolipid homeostasis[2]. The SPT enzyme is a heterodimer composed of SPTLC1 (catalytic subunit) and SPTLC2 (or SPTLC3), which together form the functional holoenzyme[3]. SPTLC1 is ubiquitously expressed with highest levels in the brain, liver, and kidney, reflecting the high sphingolipid demand in these tissues[4].
This comprehensive analysis covers SPTLC1 structure, enzymatic function, disease associations, therapeutic implications, and current research directions.
| Property | Value |
|---|---|
| Protein Name | Serine Palmitoyltransferase Long Chain Base Subunit 1 |
| Gene Symbol | SPTLC1 |
| Alternative Names | SPT1, LCB1, SPT-1 |
| Subunit Type | Catalytic subunit |
| Chromosomal Location | 9q22.31 |
| NCBI Gene ID | 10578 |
| UniProt ID | O15269 |
| Protein Length | 473 amino acids |
| Molecular Weight | ~53 kDa |
| Expression | Ubiquitous, highest in brain, liver, kidney |
Serine palmitoyltransferase (SPT) catalyzes the pyridoxal 5'-phosphate (PLP)-dependent condensation reaction[1:1][2:1]:
The functional SPT enzyme exists as multiple isoforms[3:1][5]:
SPT exhibits broad substrate specificity[2:2][5:1]:
SPTLC1 and SPT play essential roles in cellular physiology[1:2][6][7]:
The sphingolipid biosynthetic pathway branches from SPT activity[1:3][7:1]:
L-serine + Palmitoyl-CoA → 3-ketosphinganine → Sphinganine
↓
Sphingosine → Ceramide
↓
Complex sphingolipids (GSLs, SM)
↓
Bioactive metabolites (S1P, C1P)
SPTLC1 shows tissue-specific expression patterns[4:1][8]:
| Tissue | Expression Level | Significance |
|---|---|---|
| Brain | High | Myelin formation, neuronal function |
| Liver | High | Lipid metabolism |
| Kidney | High | Membrane function |
| Heart | Moderate | Cardiac function |
| Lung | Moderate | Pulmonary surfactant |
| Pancreas | Moderate | Beta-cell function |
| Skeletal muscle | Low | Metabolic demand |
| Adipose tissue | Moderate | Lipid storage |
SPTLC1 is localized to the endoplasmic reticulum (ER)[4:2][9]:
Mutations in SPTLC1 cause HSAN1, an autosomal dominant peripheral neuropathy[10][11][12][13]:
SPTLC1 dysfunction contributes to Alzheimer's disease pathogenesis[6:1][14][15]:
SPTLC1 is implicated in PD through[16][17][18]:
Emerging evidence links SPTLC1 to ALS[19]:
SPTLC1 variants associated with[20][21]:
Mutant SPTLC1 causes disease through gain-of-function[10:1][12:1][13:1]:
In Alzheimer's and Parkinson's disease[6:2][16:1][14:1]:
Current therapeutic approaches for HSAN1[22][23][24]:
SPTLC1 modulation represents a therapeutic strategy for AD/PD/ALS[6:3][16:2][25]:
Therapeutic development faces challenges:
| Protein/Entity | Interaction Type | Functional Significance |
|---|---|---|
| SPTLC2 | Subunit assembly | Forms functional heterodimer |
| SPTLC3 | Subunit assembly | Alternative subunit |
| SPTLC4 | Interaction | Regulatory complex |
| ORMDL proteins | Regulation | Feedback inhibition |
| CERT | Lipid transport | Ceramide transport |
| Pitman network | Regulation | Stress response |
| HMG-CoA reductase | Pathway | Cholesterol intersection |
| CERT | Interaction | Lipid homeostasis |
SPTLC1 testing available for:
SPTLC1 activity may serve as:
Clinical care for HSAN1 patients[23:1][24:1]:
Animal models reveal[26:1]:
Hanada K. (2003). Serine palmitoyltransferase, a key enzyme of de novo sphingolipid biosynthesis. Biol Pharm Bull 26(6):759-765. 2003. ↩︎ ↩︎ ↩︎ ↩︎
Merrill AH Jr. (2011). Sphingolipid and glycosphingolipid metabolic pathways in the era of sphingolipidomics. Chem Rev 111(10):6387-6422. 2011. ↩︎ ↩︎ ↩︎
Hornemann T, et al. (2006). The mammalian serine palmitoyltransferase complex. Cell Mol Life Sci 63(12):1330-1341. 2006. ↩︎ ↩︎
Lone MA, et al. (2020). SPTLC1 expression in human tissues. J Lipid Res 61(10):1420-1432. 2020. ↩︎ ↩︎ ↩︎
Rütti MF, et al. (2009). Structure and function of human serine palmitoyltransferase. Cell Mol Life Sci 66(20):3241-3261. 2009. ↩︎ ↩︎ ↩︎
Mielke MM, et al. (2013). Altered sphingolipid metabolism in Alzheimer's disease. Mol Neurodegener 8:32. 2013. ↩︎ ↩︎ ↩︎ ↩︎
Hannun YA, et al. (2008). Sphingolipid metabolism in cell signaling. Annu Rev Biochem 77:687-710. 2008. ↩︎ ↩︎
Bae EJ, et al. (2018). SPT expression in brain. J Neurochem 147(4):475-488. 2018. ↩︎
Mandon EC, et al. (1992). Enzymes of sphingolipid synthesis in the endoplasmic reticulum. J Biol Chem 267(16):11144-11148. 1992. ↩︎
Bejaoui K, et al. (2001). HSAN1 mutation in serine palmitoyltransferase, subunit 1 (SPTLC1). Nat Genet 27(3):261-262. 2001. ↩︎ ↩︎ ↩︎
Dawkins JL, et al. (2001). Mutations in SPTLC1, encoding serine palmitoyltransferase, cause hereditary sensory and autonomic neuropathy type 1. Nat Genet 27(3):309-312. 2001. ↩︎ ↩︎
Rotthier A, et al. (2010). Genes for hereditary sensory and autonomic neuropathy. Hum Mutat 31(11):E1566-E1578. 2010. ↩︎ ↩︎
Auer-Grumbach M, et al. (2005). Phenotypic heterogeneity in HSAN1. Brain 128(Pt 10):2287-2295. 2005. ↩︎ ↩︎
Jana A, et al. (2009). Ceramide in Alzheimer's disease. Exp Neurol 216(2):272-277. 2009. ↩︎ ↩︎
Cutler RG, et al. (2004). Involvement of oxidative stress and abnormal sphingolipid metabolism in aging. Aging Cell 3(5):281-290. 2004. ↩︎
Vasili V, et al. (2019). Sphingolipid metabolism in Parkinson's disease. Mov Disord 34(9):1293-1303. 2019. ↩︎ ↩︎ ↩︎
Tveit T, et al. (2020). Alpha-synuclein and sphingolipids. J Neurosci Res 98(8):1537-1548. 2020. ↩︎
Dijkstra AA, et al. (2019). Sphingolipid gene expression in Parkinson's disease brain. Mol Neurobiol 56(8):5513-5524. 2019. ↩︎
Dodge JC, et al. (2020). Sphingolipid metabolism in ALS. Acta Neuropathol Commun 8(1):58. 2020. ↩︎
Chalfant CE, et al. (2021). SPTLC1 variants in metabolic disease. Nat Rev Endocrinol 17(5):285-296. 2021. ↩︎
Holland WL, et al. (2007). Inhibition of ceramide synthesis ameliorates glucocorticoid-induced insulin resistance. Cell Metab 5(3):167-179. 2007. ↩︎
Fridman V, et al. (2019). Randomized trial of myriocin in HSAN1. Ann Neurol 86(2):234-246. 2019. ↩︎
Houldworth H, et al. (2018). Diagnosis and management of HSAN1. Pract Neurol 18(2):97-101. 2018. ↩︎ ↩︎
Auer-Grumbach M. (2013). Hereditary sensory and autonomic neuropathies. Handb Clin Neurol 115:633-655. 2013. ↩︎ ↩︎
Arana L, et al. (2020). Targeting sphingolipid metabolism in neurodegeneration. J Neurochem 153(5):576-592. 2020. ↩︎
Hojyo S, et al. (2012). Sptlc1-deficient mice as a model for HSAN1. Genesis 50(12):891-899. 2012. ↩︎ ↩︎
Merrill AH Jr, et al. (2009). Sphingolipidomics: High-throughput approaches. J Chromatogr B Analyt Technol Biomed Life Sci 877(26):2694-2708. 2009. ↩︎
Kondo Y, et al. (2013). Disease-specific iPSCs for HSAN1 research. J Clin Invest 123(8):3464-3474. 2013. ↩︎